Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gilteritinib + PRT062607|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gilteritinib||Xospata||ASP2215||AXL Inhibitor 29 FLT3 Inhibitor 57||Xospata (gilteritinib) is a small molecule inhibitor of FLT3 and AXL that has activity against FLT3-ITD, FLT3 F691L, and FLT3 D835 mutations, potentially resulting in decreased tumor growth (J Clin Oncol 32:5s, 2014 (suppl; abstr 7070), PMID: 25891481). Xospata (gilteritinib) is FDA approved for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation (ITD, D835X, and I836X) (FDA.gov).|
|PRT062607||P505-15|BIIB057||SYK Inhibitor 15||PRT062607 is a selective inhibitor of SYK, which may lead to decreased tumor cell growth and increased sensitivity to chemotherapeutics (PMID: 23220742, PMID: 27406873).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL Q365_E366insSK FLT3 pos||hematologic cancer||sensitive||Gilteritinib + PRT062607||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of PRT062607 to treatment with Xospata (gilteritinib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).||31943762|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|